2361290-85-7

2361290-85-7 structure

Name: Recaticimab
Chemical Name: Recaticimab
CAS Number: 2361290-85-7
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Metabolic Enzyme/Protease Ser/Thr Protease
Create Date: 2023-03-06 11:01:00
Modify Date: 2024-04-09 19:23:51
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia[1][2].

Name	Recaticimab

Description	Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Ser/Thr Protease Research Areas >> Metabolic Disease
References	[1]. Xu M, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022 Jan 18;20(1):13. [2]. Jiao J, et al. Pharmaceutical composition of pcsk9 inhibitor and glp-1 receptor agonist. World Intellectual Property Organization. WO2022268214.

No Any Chemical & Physical Properties